Gateway Capital Partners Announces Investment Opinion on Cel-Sci Corporation.LONDON--(BUSINESS WIRE)--Aug. 27, 1999-- Gateway Capital Begins Coverage of Cel-Sci Corporation (HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. ) With a STRONG BUY Recommendation and a Price Target of $105 Per Share Gateway Capital Partners Inc. announced today that it has initiated research coverage of CEL-SCI CORPORATION (AMEX AMEX See: American Stock Exchange : HIV-news) with a "STRONG BUY" recommendation and established a twelve month price target of $105.00 per share. HIV is a biopharmaceutical company developing potentially breakthrough products in the field of immunotherapy. Highlights of the Report MULTIKINE -- Multikine (Leukocyte leukocyte (l  `kəsīt'): see blood. leukocyte or white blood cell or white corpuscle Interleukin Injection) is a patented immunotherapeutic agent, which consists of a mixture of naturally occurring cytokines Cytokines Chemicals made by the cells that act on other cells to stimulate or inhibit their function. Cytokines that stimulate growth are called "growth factors. including interleukins, interferons, chemokines and colony-stimulating factors. -- Multikine activates and boosts the local immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. . -- It has induced tumor reduction and tumor necrosis tumor necrosis Death of tumor tissue, a common event in aggressive CAs in which the tumor rapidly outgrows its blood supply, resulting in tumor cell death. Cf Apoptosis. in phase I/II trials of head and neck cancer. -- Multikine has shown minimal side effects Side effects Effects of a proposed project on other parts of the firm. . -- It may be effective against all solid tumors since it is tumor nonspecific nonspecific /non·spe·cif·ic/ (non?spi-sif´ik) 1. not due to any single known cause. 2. not directed against a particular agent, but rather having a general effect. nonspecific 1. . -- Enormous market potential HGP-30W AIDS VACCINE -- HGP-30W is a prophylactic vaccine designed to induce cellular and humoral immune responses against the predominant subtypes of HIV-1 worldwide, designed to prevent or reduce the severity of infection by HIV. -- HGP-30W is based on a region of the AIDS virus that is less variable and less subject to mutation. HGP-30W produces killer T-cells to destroy the virus-infected cells -- In animal and human studies, HGP-30W has been shown to generate immune responses that potentially recognize the major HIV subtypes, representing more than 90% of the world's AIDS cases. -- It is inherently safe, since a synthetic peptide cannot cause infection, such as vaccines using infectious, attenuated Attenuated Alive but weakened; an attenuated microorganism can no longer produce disease. Mentioned in: Tuberculin Skin Test attenuated having undergone a process of attenuation. or killed viruses -- Phase II study currently ongoing in Europe -- Patent protected L.E.A.P.S - L.E.A.P.S. (Ligand Epitope epitope: see immunity. Antigen Presentation System) induces the body's immune system in a way most likely to eliminate or control disease. - L.E.A.P.S. is a modulation technology platform that may allow development of new immunotherapies and/or vaccines for infectious diseases, cancer, autoimmune diseases, allergic asthma and allergies. - Any disease for which antigenic epitope sequences have been identified, such as bacterial, viral, parasitic infections, cancer, autoimmune diseases, allergic asthma and allergy, are good candidates for this technology. - HIV, Herpes simplex, malaria, tuberculosis, prostate and breast cancer therapies under development provide enormous market potential. - Patent protected. Gateway Capital believes a premium valuation of $105 per share is well justified for Cel-Sci Corporation. "This company has potential products with extraordinary financial potential and may be the future premier biopharmaceutical company." Gateway Capital Partners Inc. provides investment research worldwide. All material herein was prepared by Gateway Capital Partners Inc. (GCP GCP Good Clinical Practice GCP Ground Control Point GCP Global Carbon Project GCP Gateway Control Protocol GCP Global Consciousness Project GCP Granulocyte Chemotactic Protein GCP Grand Central Parkway (New York) ) based upon information and sources believed to be reliable. The information contained herein is not guaranteed by GCP to be accurate, and should not be considered to be all-inclusive. This discussion contains forward-looking statements that involve risks and uncertainties. A company's actual results could differ materially from those described in any forward-looking statements or announcements discussed within. The material is for information purposes only. Please consult a broker before purchasing or selling any securities mentioned in this report. GCP has not been compensated for the preparation and distribution of this report and has issued the report on an unsolicited basis. GCP, its affiliates, and/or its officers, directors and employees may buy, sell or have a position in the securities discussed in this report. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion